<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01073293</url>
  </required_header>
  <id_info>
    <org_study_id>V503-007</org_study_id>
    <secondary_id>2010_512</secondary_id>
    <nct_id>NCT01073293</nct_id>
  </id_info>
  <brief_title>A Study of V503 Vaccine Given Concomitantly With REPEVAX™ in 11 to 15 Year Olds (V503-007)</brief_title>
  <official_title>A Phase III Open-Label Clinical Trial to Study the Immunogenicity and Tolerability of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given Concomitantly With REPEVAX™ in Preadolescents and Adolescents (11 to 15 Year Olds)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether co-administration of the first dose of V503 and REPEVAX™ is
      well tolerated and causes a non-inferior immune response when compared to administration of
      REPEVAX™ one month following the first dose of V503.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2010</start_date>
  <completion_date type="Actual">June 16, 2011</completion_date>
  <primary_completion_date type="Actual">June 16, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503</measure>
    <time_frame>4 weeks following Month 6 vaccination</time_frame>
    <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured using a competitive Luminex immunoassay. Titers are reported in milli Merck Units/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a V503 Injection-site Adverse Experience</measure>
    <time_frame>Day 1 through Day 5 following Day 1 vaccination</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received V503 vaccination were reported for this endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Repevax™ Injection-site Adverse Experience</measure>
    <time_frame>Day 1 through Day 5 following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
    <description>For the Concomitant Vaccination group, injection-site AEs are reported following Day 1 vaccination; for the Non-concomitant Vaccination group, injection-site AEs are reported following Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received Repevax™ vaccination were reported for this endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Maximum Temperature &gt;=37.8 °C (&gt;=100.0 °F) (Oral or Oral Equivalent)</measure>
    <time_frame>Up to 5 days following the Day 1 and Month 1 vaccination / visit</time_frame>
    <description>For the Concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Systemic Adverse Experience</measure>
    <time_frame>Up to 15 days following the Day 1 and Month 1 vaccination / visit</time_frame>
    <description>For the Concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body that is temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an adverse experience. A systemic AE was an AE that was not associated with the injection site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve Acceptable Titers of Anti-Diphtheria and Anti-Tetanus Antibody</measure>
    <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
    <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to diphtheria toxin were measured using a cell-based Diphtheria Micrometabolic Inhibition assay. Serum titers of neutralizing antibody to tetanus toxin were measured using an enzyme immunoassay. The lower limits of quantitation of the assays was 0.01 International Units (IU)/mL and 0.04 IU/mL, respectively. Acceptable titers refer to the World Health Organization-defined protective titer of &gt;=0.1 IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of Pertussis Antibody Responses</measure>
    <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
    <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertactin (PRN), and anti-fimbriae 2/3 (FM 2/3) antibodies were measured using enzyme-linked immunosorbent assays. Titers are expressed as enzyme-linked immunoassay units/mL (ELU/mL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieve Acceptable Titers of Anti-Poliovirus Antibody</measure>
    <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
    <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to poliovirus type 1, 2, and 3 were measured using a microneutralization assay. Serial dilutions of sera were incubated with type-specific standard poliovirus and sensitive cells. Neutralization of the virus was measured by cell staining. Acceptable titers were defined as neutralization at &gt;=1:8 dilution of serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Seroconvert for Each of the HPV Types</measure>
    <time_frame>Month 7</time_frame>
    <description>Blood was drawn at Month 7 and assayed to determine whether or not a participant had achieved seroconversion for the HPV types. The lower limit of the titer (milli Merck U/mL) considered seropositive was as follows: HPV Type 6: &gt;=30, HPV Type 11: &gt;=16; HPV Type 16: &gt;=20, HPV Type 18: &gt;=24, HPV Type 31: &gt;=10, HPV Type 33: &gt;=8, HPV Type 45: &gt;=8, HPV Type 52: &gt;=8, and HPV Type 58: &gt;=8.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1054</enrollment>
  <condition>Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-concomitant Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V503 Vaccine</intervention_name>
    <description>V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6</description>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
    <arm_group_label>Non-concomitant Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REPEVAX™ (Concomitant)</intervention_name>
    <description>REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1</description>
    <arm_group_label>Concomitant Vaccination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>REPEVAX™ (Non-concomitant)</intervention_name>
    <description>REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1</description>
    <arm_group_label>Non-concomitant Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Participant is in good health

          -  Participant's parent/legal guardian can read, understand, and complete the vaccination
             report card

          -  Participant is not sexually active and does not plan on becoming sexually active
             during the study

          -  Participant has received a documented full primary immunization series against
             diphtheria, tetanus, pertussis, and poliovirus (inactivated and/or oral poliovirus),
             but not in the last 5 years. There must be a 5-year interval from a prior vaccination
             containing any one of these vaccine antigens.

        Exclusion Criteria:

          -  Participant has a known allergy to any vaccine component of V503 or REPEVAX™

          -  Participant has had a severe reaction affecting the brain (e.g., evolving
             encephalopathy) within 7 days after a previous dose of a pertussis-containing vaccine

          -  Participant has had a progressive severe illness affecting the brain after a previous
             dose of tetanus, diphtheria, poliovirus or a component pertussis combination
             (acellular and whole cell) vaccine

          -  Participant ever had Guillain-Barré syndrome or brachial neuritis following a previous
             dose of a tetanus-containing vaccine

          -  Participant has a condition that is a contraindication to vaccination as indicated in
             the most up to date package inserts of REPEVAX™

          -  Participant has a history of severe allergic reaction that required medical
             intervention

          -  Participant has hemophilia, thrombocytopenia, is receiving anticoagulation therapy
             and/or has any coagulation disorder that would contraindicate intramuscular injections

          -  Participant is concurrently enrolled in clinical studies of investigational agents

          -  Female participant is pregnant

          -  Participant has donated blood within 1 week prior to first study vaccination, or
             intends to donate during the study

          -  Participant is immunocompromised, immunodeficient, or has an autoimmune condition

          -  Participant has had a splenectomy

          -  Participant has received immunosuppressive therapies in the prior year

          -  Participant has received immune globulin product or blood-derived product in the last
             3 months

          -  Participant has received inactivated vaccine(s) within 14 days or live vaccine(s)
             within 21 days of first study vaccination

          -  Participant has received a marketed HPV vaccine or has participated in an HPV vaccine
             trial

          -  Participant has received a tetanus, diphtheria, pertussis, or poliovirus (inactivated
             and/or oral poliovirus) vaccination within the last 5 years

          -  Participant has a fever ≥100°F within 24 hours of vaccination

          -  Participant has any history or current condition, therapy, lab abnormality, or other
             circumstance such that it is not in the best interest of the participant to
             participate

          -  Participant and parent/legal guardian are unable to give assent/consent

          -  Participant is unlikely to adhere to the study procedures or is planning to relocate
             during the study

          -  Participant has recent history of illicit drug or alcohol abuse

          -  Participant has a history of HPV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Thailand</country>
  </removed_countries>
  <results_reference>
    <citation>Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-ter Meulen A. An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015 Jun;34(6):627-34. doi: 10.1097/INF.0000000000000694.</citation>
    <PMID>25831420</PMID>
  </results_reference>
  <results_reference>
    <citation>Moreira ED Jr, Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, Kosalaraksa P, Schilling A, Van Damme P, Bornstein J, Bosch FX, Pils S, Cuzick J, Garland SM, Huh W, Kjaer SK, Qi H, Hyatt D, Martin J, Moeller E, Ritter M, Baudin M, Luxembourg A. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016 Aug;138(2). pii: e20154387. doi: 10.1542/peds.2015-4387. Epub 2016 Jul 15.</citation>
    <PMID>27422279</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2010</study_first_posted>
  <results_first_submitted>December 12, 2014</results_first_submitted>
  <results_first_submitted_qc>December 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2014</results_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=V503-007&amp;kw=V503-007&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
        </group>
        <group group_id="P2">
          <title>Non-concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="526"/>
                <participants group_id="P2" count="528"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="521"/>
                <participants group_id="P2" count="517"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
        </group>
        <group group_id="B2">
          <title>Non-concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="526"/>
            <count group_id="B2" value="528"/>
            <count group_id="B3" value="1054"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.4" spread="1.2"/>
                    <measurement group_id="B2" value="12.4" spread="1.2"/>
                    <measurement group_id="B3" value="12.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="528"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503</title>
        <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured using a competitive Luminex immunoassay. Titers are reported in milli Merck Units/mL.</description>
        <time_frame>4 weeks following Month 6 vaccination</time_frame>
        <population>The per-protocol population included participants who received all study vaccinations, were seronegative to HPV on Day 1, and had serum samples available for evaluation of the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503</title>
          <description>Serum antibody titers for HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 were measured using a competitive Luminex immunoassay. Titers are reported in milli Merck Units/mL.</description>
          <population>The per-protocol population included participants who received all study vaccinations, were seronegative to HPV on Day 1, and had serum samples available for evaluation of the endpoint</population>
          <units>milli Merck Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6: n=477, 461</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1637.9" lower_limit="8.0" upper_limit="24405.0"/>
                    <measurement group_id="O2" value="1725.0" lower_limit="173.0" upper_limit="12040.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11: n=479, 462</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1170.3" lower_limit="84.0" upper_limit="13438.0"/>
                    <measurement group_id="O2" value="1212.6" lower_limit="153.0" upper_limit="9816.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16: n=489, 479</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6529.4" lower_limit="689.0" upper_limit="76781.0"/>
                    <measurement group_id="O2" value="6940.6" lower_limit="841.0" upper_limit="49390.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV18: n=486, 475</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1854.1" lower_limit="81.0" upper_limit="38887.0"/>
                    <measurement group_id="O2" value="1954.8" lower_limit="49.0" upper_limit="15582.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31: n=485, 473</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1646.2" lower_limit="88.0" upper_limit="22848.0"/>
                    <measurement group_id="O2" value="1750.6" lower_limit="118.0" upper_limit="32822.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33: n=487, 478</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823.8" lower_limit="54.0" upper_limit="6563.0"/>
                    <measurement group_id="O2" value="915.5" lower_limit="110.0" upper_limit="7058.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45: n=489, 478</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="658.2" lower_limit="28.0" upper_limit="14131.0"/>
                    <measurement group_id="O2" value="675.6" lower_limit="29.0" upper_limit="8725.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52: n=490, 479</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="965.4" lower_limit="45.0" upper_limit="11730.0"/>
                    <measurement group_id="O2" value="1015.3" lower_limit="79.0" upper_limit="14392.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58: n=484, 469</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1188.8" lower_limit="102.0" upper_limit="13681.0"/>
                    <measurement group_id="O2" value="1334.8" lower_limit="106.0" upper_limit="14752.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 6</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 11</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 16</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 18</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 31</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 33</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 45</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 52</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-HPV 58</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.5</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a V503 Injection-site Adverse Experience</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received V503 vaccination were reported for this endpoint.</description>
        <time_frame>Day 1 through Day 5 following Day 1 vaccination</time_frame>
        <population>The population analyzed included all vaccinated participants with follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a V503 Injection-site Adverse Experience</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received V503 vaccination were reported for this endpoint.</description>
          <population>The population analyzed included all vaccinated participants with follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Repevax™ Injection-site Adverse Experience</title>
        <description>For the Concomitant Vaccination group, injection-site AEs are reported following Day 1 vaccination; for the Non-concomitant Vaccination group, injection-site AEs are reported following Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received Repevax™ vaccination were reported for this endpoint.</description>
        <time_frame>Day 1 through Day 5 following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
        <population>The population analyzed included all vaccinated participants with follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Repevax™ Injection-site Adverse Experience</title>
          <description>For the Concomitant Vaccination group, injection-site AEs are reported following Day 1 vaccination; for the Non-concomitant Vaccination group, injection-site AEs are reported following Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an AE. Only injection-site AEs in the arm that received Repevax™ vaccination were reported for this endpoint.</description>
          <population>The population analyzed included all vaccinated participants with follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="520"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.0"/>
                    <measurement group_id="O2" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Maximum Temperature &gt;=37.8 °C (&gt;=100.0 °F) (Oral or Oral Equivalent)</title>
        <description>For the Concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 vaccination.</description>
        <time_frame>Up to 5 days following the Day 1 and Month 1 vaccination / visit</time_frame>
        <population>The population analyzed included all vaccinated participants with follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Maximum Temperature &gt;=37.8 °C (&gt;=100.0 °F) (Oral or Oral Equivalent)</title>
          <description>For the Concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, temperatures were collected after the Day 1 vaccination and the Month 1 vaccination.</description>
          <population>The population analyzed included all vaccinated participants with follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Systemic Adverse Experience</title>
        <description>For the Concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body that is temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an adverse experience. A systemic AE was an AE that was not associated with the injection site.</description>
        <time_frame>Up to 15 days following the Day 1 and Month 1 vaccination / visit</time_frame>
        <population>The population analyzed included all vaccinated participants with follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Systemic Adverse Experience</title>
          <description>For the Concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 visit; for the Non-concomitant Vaccination group, systemic AEs were collected after the Day 1 vaccination and the Month 1 vaccination. An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body that is temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the vaccine is also an adverse experience. A systemic AE was an AE that was not associated with the injection site.</description>
          <population>The population analyzed included all vaccinated participants with follow-up</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="527"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieve Acceptable Titers of Anti-Diphtheria and Anti-Tetanus Antibody</title>
        <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to diphtheria toxin were measured using a cell-based Diphtheria Micrometabolic Inhibition assay. Serum titers of neutralizing antibody to tetanus toxin were measured using an enzyme immunoassay. The lower limits of quantitation of the assays was 0.01 International Units (IU)/mL and 0.04 IU/mL, respectively. Acceptable titers refer to the World Health Organization-defined protective titer of &gt;=0.1 IU/mL.</description>
        <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
        <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Acceptable Titers of Anti-Diphtheria and Anti-Tetanus Antibody</title>
          <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to diphtheria toxin were measured using a cell-based Diphtheria Micrometabolic Inhibition assay. Serum titers of neutralizing antibody to tetanus toxin were measured using an enzyme immunoassay. The lower limits of quantitation of the assays was 0.01 International Units (IU)/mL and 0.04 IU/mL, respectively. Acceptable titers refer to the World Health Organization-defined protective titer of &gt;=0.1 IU/mL.</description>
          <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-diphtheria titer &gt;=0.1 IU/mL: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.9" upper_limit="100"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-tetanus titer &gt;=0.1 IU/mL: n=504, 472</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O2" value="99.6" lower_limit="98.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-diphtheria titer &gt;=0.1 IU/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the percentage difference is greater than -10</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-tetanus titer &gt;=0.1 IU/mL</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the percentage difference is greater than -10</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Pertussis Antibody Responses</title>
        <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertactin (PRN), and anti-fimbriae 2/3 (FM 2/3) antibodies were measured using enzyme-linked immunosorbent assays. Titers are expressed as enzyme-linked immunoassay units/mL (ELU/mL).</description>
        <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
        <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Pertussis Antibody Responses</title>
          <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of anti-pertussis toxin (PT), anti-filamentous hemagglutinin (FHA), anti-pertactin (PRN), and anti-fimbriae 2/3 (FM 2/3) antibodies were measured using enzyme-linked immunosorbent assays. Titers are expressed as enzyme-linked immunoassay units/mL (ELU/mL).</description>
          <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
          <units>ELU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT: n=505, 473</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" lower_limit="38.4" upper_limit="44.9"/>
                    <measurement group_id="O2" value="43.8" lower_limit="40.4" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.1" lower_limit="176.2" upper_limit="200.8"/>
                    <measurement group_id="O2" value="190.6" lower_limit="178.1" upper_limit="203.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="372.9" lower_limit="334.8" upper_limit="415.2"/>
                    <measurement group_id="O2" value="398.2" lower_limit="356.3" upper_limit="445.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FIM 2/3: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378.2" lower_limit="324.4" upper_limit="440.9"/>
                    <measurement group_id="O2" value="423.6" lower_limit="361.5" upper_limit="496.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-PT</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-FHA</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Fold difference in GMT</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-PRN</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.67</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
            <param_type>Difference in GMT</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anti-FIM 2/3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the lower limit of the 95% confidence interval for the fold difference is &gt;0.67</non_inferiority_desc>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
            <param_type>Difference in GMT</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieve Acceptable Titers of Anti-Poliovirus Antibody</title>
        <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to poliovirus type 1, 2, and 3 were measured using a microneutralization assay. Serial dilutions of sera were incubated with type-specific standard poliovirus and sensitive cells. Neutralization of the virus was measured by cell staining. Acceptable titers were defined as neutralization at &gt;=1:8 dilution of serum.</description>
        <time_frame>4 weeks following Day 1 (Concomitant) or Month 1 (Non-concomitant) vaccination</time_frame>
        <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieve Acceptable Titers of Anti-Poliovirus Antibody</title>
          <description>For the Concomitant Vaccination group, serum samples were collected 4 weeks after the Day 1 vaccination; for the Non-concomitant Vaccination group, serum samples were collected 4 weeks after the Month 1 vaccination. Titers of neutralizing antibody to poliovirus type 1, 2, and 3 were measured using a microneutralization assay. Serial dilutions of sera were incubated with type-specific standard poliovirus and sensitive cells. Neutralization of the virus was measured by cell staining. Acceptable titers were defined as neutralization at &gt;=1:8 dilution of serum.</description>
          <population>The per-protocol population included participants who received vaccination and had serum samples available for evaluation of the endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poliovirus type 1: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="99.8" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 2: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.6" lower_limit="98.4" upper_limit="100"/>
                    <measurement group_id="O2" value="99.8" lower_limit="98.7" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 3: n=505, 474</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 1</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the difference is statistically less than 10 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 2</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the difference is statistically less than 10 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 3</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority of concomitant versus non-concomitant vaccination is demonstrated if the difference is statistically less than 10 percentage points</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Difference in percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Seroconvert for Each of the HPV Types</title>
        <description>Blood was drawn at Month 7 and assayed to determine whether or not a participant had achieved seroconversion for the HPV types. The lower limit of the titer (milli Merck U/mL) considered seropositive was as follows: HPV Type 6: &gt;=30, HPV Type 11: &gt;=16; HPV Type 16: &gt;=20, HPV Type 18: &gt;=24, HPV Type 31: &gt;=10, HPV Type 33: &gt;=8, HPV Type 45: &gt;=8, HPV Type 52: &gt;=8, and HPV Type 58: &gt;=8.</description>
        <time_frame>Month 7</time_frame>
        <population>The per-protocol population included participants who received all study vaccinations, were seronegative to HPV on Day 1, and had serum samples available for evaluation of the endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1</description>
          </group>
          <group group_id="O2">
            <title>Non-concomitant Vaccination</title>
            <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Seroconvert for Each of the HPV Types</title>
          <description>Blood was drawn at Month 7 and assayed to determine whether or not a participant had achieved seroconversion for the HPV types. The lower limit of the titer (milli Merck U/mL) considered seropositive was as follows: HPV Type 6: &gt;=30, HPV Type 11: &gt;=16; HPV Type 16: &gt;=20, HPV Type 18: &gt;=24, HPV Type 31: &gt;=10, HPV Type 33: &gt;=8, HPV Type 45: &gt;=8, HPV Type 52: &gt;=8, and HPV Type 58: &gt;=8.</description>
          <population>The per-protocol population included participants who received all study vaccinations, were seronegative to HPV on Day 1, and had serum samples available for evaluation of the endpoint</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="525"/>
                <count group_id="O2" value="528"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV 6: n=477, 461</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 11: n=479, 462</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16: n=489, 479</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18: n=486, 475</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31: n=485, 473</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33: n=487, 478</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45: n=489, 478</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52: n=490, 479</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58: n=484, 469</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events: up to Month 7; Other adverse events: Day 1 through Day 5 following any vaccination for injection-site AEs and Day 1 through Day 15 following any vaccination for non-injection-site AEs</time_frame>
      <desc>Adverse events were collected for all participants who received at least one dose of V503 and Repevax™</desc>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Day 1</description>
        </group>
        <group group_id="E2">
          <title>Non-concomitant Vaccination</title>
          <description>V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="525"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="525"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="509" subjects_at_risk="525"/>
                <counts group_id="E2" subjects_affected="505" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="525"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="42" subjects_affected="39" subjects_at_risk="525"/>
                <counts group_id="E2" events="46" subjects_affected="36" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="351" subjects_affected="228" subjects_at_risk="525"/>
                <counts group_id="E2" events="290" subjects_affected="185" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="1500" subjects_affected="501" subjects_at_risk="525"/>
                <counts group_id="E2" events="1463" subjects_affected="493" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Injection-site pruritus</sub_title>
                <counts group_id="E1" events="31" subjects_affected="28" subjects_at_risk="525"/>
                <counts group_id="E2" events="36" subjects_affected="27" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="528" subjects_affected="295" subjects_at_risk="525"/>
                <counts group_id="E2" events="403" subjects_affected="230" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="105" subjects_affected="88" subjects_at_risk="525"/>
                <counts group_id="E2" events="86" subjects_affected="71" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="525"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="527"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="525"/>
                <counts group_id="E2" events="31" subjects_affected="27" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="265" subjects_affected="167" subjects_at_risk="525"/>
                <counts group_id="E2" events="200" subjects_affected="140" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="525"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="527"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

